These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
696 related articles for article (PubMed ID: 29019095)
21. Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer. Schrauder MG; Brunel-Geuder L; Häberle L; Wunderle M; Hoyer J; Reis A; Schulz-Wendtland R; Beckmann MW; Lux MP Breast; 2017 Apr; 32():186-191. PubMed ID: 28214786 [TBL] [Abstract][Full Text] [Related]
22. Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers. Havrilesky LJ; Moss HA; Chino J; Myers ER; Kauff ND Gynecol Oncol; 2017 Jun; 145(3):549-554. PubMed ID: 28390820 [TBL] [Abstract][Full Text] [Related]
23. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. Kauff ND; Domchek SM; Friebel TM; Robson ME; Lee J; Garber JE; Isaacs C; Evans DG; Lynch H; Eeles RA; Neuhausen SL; Daly MB; Matloff E; Blum JL; Sabbatini P; Barakat RR; Hudis C; Norton L; Offit K; Rebbeck TR J Clin Oncol; 2008 Mar; 26(8):1331-7. PubMed ID: 18268356 [TBL] [Abstract][Full Text] [Related]
24. An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Madorsky-Feldman D; Sklair-Levy M; Perri T; Laitman Y; Paluch-Shimon S; Schmutzler R; Rhiem K; Lester J; Karlan BY; Singer CF; Van Maerken T; Claes K; Brunet J; Izquierdo A; Teulé A; Lee JW; Kim SW; Arun B; Jakubowska A; Lubinski J; Tucker K; Poplawski NK; Varesco L; Bonelli LA; Buys SS; Mitchell G; Tischkowitz M; Gerdes AM; Seynaeve C; Robson M; Kwong A; Tung N; Tessa N; Domchek SM; Godwin AK; Rantala J; Arver B; Friedman E Breast Cancer Res Treat; 2016 Jun; 157(2):319-327. PubMed ID: 27117159 [TBL] [Abstract][Full Text] [Related]
25. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P; Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637 [TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations. Salyer C; Kobelka C; Barrie A; Weintraub MR; Powell CB Gynecol Oncol; 2019 Aug; 154(2):374-378. PubMed ID: 31160070 [TBL] [Abstract][Full Text] [Related]
27. Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan. Nomura H; Abe A; Fusegi A; Yoshimitsu T; Misaka S; Murakami A; Matsumoto T; Tsumura S; Kanno M; Aoki Y; Netsu S; Omi M; Tanigawa T; Okamoto S; Omatsu K; Yunokawa M; Kanao H; Habano E; Arakawa H; Kaneko K; Ueki A; Haruyama Y; Inari H; Ueno T Sci Rep; 2023 Jan; 13(1):1018. PubMed ID: 36658289 [TBL] [Abstract][Full Text] [Related]
28. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy. Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873 [TBL] [Abstract][Full Text] [Related]
29. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397 [TBL] [Abstract][Full Text] [Related]
30. Uptake and efficacy of bilateral risk reducing surgery in unaffected female Marcinkute R; Woodward ER; Gandhi A; Howell S; Crosbie EJ; Wissely J; Harvey J; Highton L; Murphy J; Holland C; Edmondson R; Clayton R; Barr L; Harkness EF; Howell A; Lalloo F; Evans DG J Med Genet; 2022 Feb; 59(2):133-140. PubMed ID: 33568438 [TBL] [Abstract][Full Text] [Related]
31. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
32. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. Kim D; Kang E; Hwang E; Sun Y; Hwang Y; Yom CK; Kim K; No JH; Kim YB; Kim SW Fam Cancer; 2013 Dec; 12(4):621-8. PubMed ID: 23504064 [TBL] [Abstract][Full Text] [Related]
33. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255 [TBL] [Abstract][Full Text] [Related]
34. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180 [TBL] [Abstract][Full Text] [Related]
35. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Beattie MS; Crawford B; Lin F; Vittinghoff E; Ziegler J Genet Test Mol Biomarkers; 2009 Feb; 13(1):51-6. PubMed ID: 19309274 [TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Schwartz MD; Isaacs C; Graves KD; Poggi E; Peshkin BN; Gell C; Finch C; Kelly S; Taylor KL; Perley L Cancer; 2012 Jan; 118(2):510-7. PubMed ID: 21717445 [TBL] [Abstract][Full Text] [Related]
37. Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline Lim H; Kim SI; Hyun S; Lee GB; Seol A; Lee M Yonsei Med J; 2021 Dec; 62(12):1090-1097. PubMed ID: 34816639 [TBL] [Abstract][Full Text] [Related]
38. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Mavaddat N; Antoniou AC; Mooij TM; Hooning MJ; Heemskerk-Gerritsen BA; ; Noguès C; Gauthier-Villars M; Caron O; Gesta P; Pujol P; Lortholary A; ; Barrowdale D; Frost D; Evans DG; Izatt L; Adlard J; Eeles R; Brewer C; Tischkowitz M; Henderson A; Cook J; Eccles D; ; van Engelen K; Mourits MJE; Ausems MGEM; Koppert LB; Hopper JL; John EM; Chung WK; Andrulis IL; Daly MB; Buys SS; ; Benitez J; Caldes T; Jakubowska A; Simard J; Singer CF; Tan Y; Olah E; Navratilova M; Foretova L; Gerdes AM; Roos-Blom MJ; Van Leeuwen FE; Arver B; Olsson H; Schmutzler RK; Engel C; Kast K; Phillips KA; Terry MB; Milne RL; Goldgar DE; Rookus MA; Andrieu N; Easton DF; ; ; Breast Cancer Res; 2020 Jan; 22(1):8. PubMed ID: 31948486 [TBL] [Abstract][Full Text] [Related]
39. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer]. Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676 [TBL] [Abstract][Full Text] [Related]
40. Increased Overall Mortality Even after Risk Reducing Surgery for Öfverholm A; Einbeigi Z; Wigermo A; Holmberg E; Karsson P Genes (Basel); 2019 Dec; 10(12):. PubMed ID: 31888263 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]